Webinars and Commercial Conversations — Register Now
Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Awareness Technology
| Company | Awareness Technology |
|---|---|
| Name of instrument | ChemWell 2910 |
| Contact | Rafael Castillo |
| City, State | Palm City, FL |
| Phone | 772-283-6540 |
| Website | |
| Type of instrument | combination chemistry/immunoassay |
| Operational type/Model type | batch, random access, discrete/benchtop |
| List price/First year sold in U.S. | $29,000/1998 |
| Targeted hospital bed size/Targeted test volume | 200/daily: 200–500; monthly: 200–400 |
| Company manufactures instrument | yes (also sold by GMI, Monobind, ASI, others) |
| Other models in this family of analyzers | ChemWell Fusion, ChemWell-T, ChemWell 2902 |
| No. of units in clinical use in U.S./Outside U.S. (countries) | 500/7,000 (worldwide) |
| Dimensions (H × W × D)/Instrument footprint | 18.625 × 36.25 × 21.5 in./< 7.905 sq. ft. |
| Weight empty/Weight fully loaded | 77 lbs./78 lbs. |
| No. of different measured assays onboard simultaneously | 15 (12 can be run and calibrated at one time) |
| No. of user-definable (open chemistry) channels | — |
| Test throughput per hour/Assay run time | 200 (27 tests in throughput)/6–120 min. |
| No. of direct ion-selective electrode channels | — |
| Detection methods | photometry |
| Stat time until completion/specimen throughput for ion-selective electrode | — |
| Stat time until completion/specimen throughput for basic metabolic panel | assay dependent |
| Stat time until completion/specimen throughput for complete metabolic panel | assay dependent |
| Typical time delay from ordering stat test until aspiration of sample | assay dependent |
| Fully automated microplate immunoassay system | yes (27–44 tests per unit; 96 wells per microplate) |
| Methodologies supported | enzyme immunoassay, colorimetric analysis |
| Separation methodologies | none necessary, coated microwell |
| Stat time until completion of a ß-hCG test | assay dependent |
| Stat time until completion of a cTn test | assay dependent |
| • Typical time delay from test order to aspiration of sample | assay dependent |
| Approximate No. of tests per reagent set/Reagent type | assay dependent/open reagent system |
| Reagents refrigerated onboard/Reagents ready to use | yes (12°–15°C on optional cooling accessory)/yes |
| Reagent lot tracking/Reagent inventory | yes/yes |
| Reagent form/Reagents barcoded | liquid chemistry (open reagent system)/yes |
| Separate reagent pack for each specimen/for each test run | no/yes |
| Walkaway capability/Walkaway duration | yes/480 min. |
| Design of sample-handling system | rack (custom reagent and sample racks) |
| Uses washable cuvettes/Uses disposable cuvettes | yes/yes |
| Min.–max. sample volume that can be aspirated at one time | 2–250 µL |
| Min. reaction volume/Min. specimen volume/Min. dead volume | 100 µL/100 µL/100 µL |
| Dedicated pediatric sample cup | no |
| Primary tube sampling | yes |
| Accommodates most standard tube sizes/Accepts nonstandard tube sizes | yes/yes (13 mm) |
| Pierces caps on primary tubes | no |
| Protects against probe collision | yes |
| Detects clots/liquid level/short sample | no/yes/yes |
| Detection or quantitation for hemolysis, icterus, lipemia, clots | assay dependent |
| Dilutes patient samples onboard/Susceptibility to carryover | yes (can be programmed to perform dilutions prior to analysis)/no carryover |
| Automatic rerun capability | yes |
| Sample volume can be diluted to rerun out-of-linear-range high results | yes |
| Sample volume can be concentrated to rerun out-of-linear-range low results | yes |
| Autocalibration/Multipoint calibration supported | no (calibrants can be stored onboard)/yes (recommended avg. frequency: test dependent) |
| Typical calibration frequency for ISE/therapeutic drugs/drugs of abuse/general chemistries/immunoassays | — |
| Automatic programmable start/Automatic programmable shutdown | no/no |
| Onboard real-time QC/Onboard software capability to review QC | yes/yes |
| Supports multiple QC lot numbers per analyte | yes |
| Waste management | manually by user or automated collection onboard instrument or direct to drain |
| Sample barcode-reading capability/Autodiscrimination | yes (Code 39, Code 129)/no |
| Lab can control analyzer from remote computer | yes |
| Instrument can diagnose its own malfunctions | yes (operator intervention required to order parts) |
| System malfunctions can be diagnosed via remote monitoring | yes |
| UPS backup power supply | no |
| Data-management capability/LIS or EHR systems interfaced | onboard/— |
| LIS interface provided/Bidirectional interface capability | yes/yes |
| Modem servicing provided/Service engineer on-site response time | no/72 hrs. |
| Mean time between failures | 1–2 service visits per year (displays error codes for troubleshooting) |
| Average scheduled maintenance time by lab personnel | daily: 15 min. |
| Maintenance records kept onboard for user/vendor | no/no |
| Maintenance training demonstration module onboard | no |
| Training included with purchase/Avg. time for basic user training | yes (1 training slot)/4 days (at customer or vendor site) |
| Advanced operator training/Extra charge for follow-up or advanced training | yes (at customer or vendor site)/yes |
| Warranty provided/Cost of annual service contract (24 h/7 d) | yes (1 year from date of shipment)/contract dependent |
| Distinguishing features (supplied by company) | vertical plate reading for biochemistries; 2-in-1 utility with the ability to run in ELISA mode or biochemistry mode; low-cost analyzer that saves on reagent use; open system; remote access; software included (free) |